Fundz

NeoGenomics

Fort Myers, Florida, United States · Biotechnology, Health Care, Health Diagnostics

Neogenomics is a leading cancer diagnostics company, providing comprehensive laboratory services. They specialize in genetic testing and next-generation sequencing to enhance cancer treatment. The company aims to improve patient outcomes through innovative diagnostics. With consistent revenue growth, Neogenomics is expanding its influence in the clinical diagnostics market.

Key facts

Headquarters
Fort Myers, Florida, United States
Employees
1,598
Industries
Biotechnology, Health Care, Health Diagnostics
Status
Public (NEO)
Website
neogenomics.com
LinkedIn
Company page

Recent activity at NeoGenomics

  • : NeoGenomics Appoints Warren Stone as Chief Executive Officer
  • : SEC 8-K (5.02): On September 30, 2026, the Board of Directors approved the appointment of Warren Stone as Chief Executive Officer of the Company, effective January 4, 2027, transitioning from his role as President and Chief Operating Officer. Concurrently, the current CEO, Tony Zook, will take on the role of Executive Chairman effective the same date. An Amended and Restated Employment Agreement was entered into with Mr. Stone, establishing a base salary of $850,000 per year and a target annual incentive bonus of 100% of his base salary. Additionally, he will be eligible for annual equity incentive awards valued at approximately $8,000,000 starting in FY 2027, pending Board discretion. This transition brings strategic implications for leadership continuity within the Company and aligns compensation with performance-based metrics.
  • : SEC 8-K (5.02): On August 11, 2026, NeoGenomics, Inc. announced the departure of Alicia Olivo from her position as EVP, General Counsel & Business Development, effective September 21, 2026. Ms. Olivo will remain an employee until October 2, 2026, for transitional purposes. As part of her departure, she will receive separation payments and benefits as per the terms of her employment agreement, which was referenced in the Company's previous 10-K filing. This transition marks a significant leadership change within the Company's legal and business development departments.
  • : SEC 8-K (8.01):
  • : SEC 8-K (5.02): On June 23, 2026, NeoGenomics, Inc. increased the size of its Board of Directors from nine to ten members by appointing Carolyn S. Starrett as a new director to fill the vacancy. Ms. Starrett will serve until the 2027 annual meeting of stockholders, receiving compensation in line with the existing director compensation program. This change reflects a strategic move to enhance governance and oversight as the Company continues to grow and evolve.
  • : SEC 8-K (1.01): On June 22, 2026, NeoGenomics, Inc. completed an offering of $275.0 million in 0.75% Convertible Senior Notes due 2032, which was later increased by an additional $41.25 million when initial purchasers exercised their option. The Notes are issued under an Indenture with U.S. Bank Trust Company, National Association, and are senior unsecured obligations of the Company. The Notes carry an interest rate of 0.75% per annum, with a conversion feature allowing noteholders to convert under certain conditions, with an initial conversion price set at approximately $14.16 per share, reflecting a 35.0% premium over the last reported sale price of $10.49 as of June 16, 2026. These developments signify a significant financial maneuver for the Company, potentially enhancing its capital structure to support future growth.
  • : SEC 8-K (8.01): On June 17, 2026, NeoGenomics, Inc. issued a press release concerning the pricing of its offering of convertible senior notes due 2032. The notes are targeted towards qualified institutional buyers following Rule 144A of the Securities Act of 1933. This offering, known as the Convertible Notes Offering, does not constitute a direct invitation for purchases or sales of securities in jurisdictions where it would be unlawful. The issuance's key details, including conditions surrounding the offering, are included in Exhibit 99.1 attached to this filing.
  • : SEC 8-K (8.01): On June 15, 2026, NeoGenomics, Inc. issued a press release regarding the commencement of its Convertible Notes Offering, which consists of convertible senior notes due 2032 aimed at qualified institutional buyers under Rule 144A of the Securities Act of 1933. The offering does not constitute an offer or solicitation in jurisdictions where it is unlawful. This action reflects NeoGenomics' strategy to raise capital through structured debt instruments, which may enhance their liquidity and financial flexibility. A copy of the press release has been included as Exhibit 99.1 in this 8-K filing.
  • : SEC 8-K (5.02): On May 21, 2026, NeoGenomics, Inc. approved an amendment to its 2023 Equity Incentive Plan to increase the shares authorized for issuance by 5,000,000. This amendment was contingent on stockholder approval, which occurred during the Annual Meeting held on the same day. At the meeting, stockholders also elected nine directors to serve until the next annual meeting, with the majority of votes in favor of each candidate. Furthermore, the advisory proposal regarding the compensation of Named Executive Officers was positively received, with over 83% of votes cast in favor, indicating strong shareholder support for key management arrangements. The effective date of this amendment and corporate governance changes is notably May 21, 2026.
  • : SEC 8-K (5.02): On January 12, 2026, the Company announced that Jeffrey S. Sherman, the Chief Financial Officer, notified the Board of Directors of his intention to retire effective April 14, 2026. Mr. Sherman will transition to the role of Executive Vice President, Finance on March 2, 2026, following the completion of the Company's audit for the fiscal year ended December 31, 2025. The Board appointed Abhishek Jain as Executive Vice President, Finance effective January 12, 2025, who will assume the Chief Financial Officer role on March 2, 2026. Mr. Jain's compensation includes an annual base salary of $520,000 with a target bonus of 60%. Significant agreements related to these changes are expected to be formalized prior to Mr. Sherman's retirement.

Leadership

  • Tony Zook, Chairman
  • Warren Stone, Chief Executive Officer
  • Jeff Sherman, Chief Financial Officer
  • Melody Harris, President

Verified email and direct lines for NeoGenomics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

NeoGenomics files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Nov 2026.

NeoGenomics in the news

Companies similar to NeoGenomics

About NeoGenomics: questions and answers

What does NeoGenomics do?

Neogenomics is a leading cancer diagnostics company, providing comprehensive laboratory services. They specialize in genetic testing and next-generation sequencing to enhance cancer treatment. The company aims to improve patient outcomes through innovative diagnostics. With consistent revenue growth, Neogenomics is expanding its influence in the clinical diagnostics market.

Where is NeoGenomics headquartered?

NeoGenomics is headquartered in Fort Myers, Florida, United States.

How many employees does NeoGenomics have?

NeoGenomics has about 1,598 employees.

Who leads NeoGenomics?

Warren Stone is a Chief Executive Officer at NeoGenomics.

What is the latest news on NeoGenomics?

On Oct 06, 2026, NeoGenomics Appoints Warren Stone as Chief Executive Officer

Is NeoGenomics a public company?

Yes. NeoGenomics is publicly traded under the ticker NEO.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches NeoGenomics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.